Accordingly, in a further aspect, the present invention provides a compound identified as an agonist or an antagonist of GPR40 for use in therapy, in particular for treating type II diabetes (non-insulin dependent daibetes mellitus, NIDDM) and obesity, glucose intolerance, insulin resistance, neurodegenerative disease (for example Alzheimer's disease) and other indications such as stroke, among ot